Filing Flows › Madrigal Pharmaceuticals (MDGL) › Q2 2026 › vs Q2 2025
Madrigal Pharmaceuticals (MDGL) Q2 2026 vs Q2 2025 (year over year)
Madrigal Pharmaceuticals's revenue rose $151M (+71%) from $213M in Q2 2025 to $364M in Q2 2026.
Madrigal Pharmaceuticals, Q2 2026: revenue $364M (+71% year over year), operating margin -15.5%, net loss $57.9M, operating cash flow $23.3M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 5.2% | -22.1% | +27.3 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $364M | $213M | $151M | +71% |
| Net loss | $57.9M | $42.3M | $15.7M | +37% |
| Costs & expenses | $422M | $260M | $162M | +62% |
| Operating costs | $421M | $260M | $161M | +62% |
| Interest & other, net | $1.6M | −$4.9M | $6.6M | — |
| Research & development | $91.2M | $54.1M | $37.1M | +69% |
| SG&A | $289M | $197M | $92.5M | +47% |
| Other operating costs | $40.0M | $9.1M | $30.9M | +341% |
| Operating cash sources | $81.3M | −$4.8M | $86.0M | — |
| Depreciation & amortization | $381K | $377K | $4K | +1% |
| Share-based compensation | $35.4M | $25.2M | $10.2M | +41% |
| Working capital & other | $45.5M | −$30.3M | $75.8M | — |
| Net loss absorbed | $57.9M | $42.3M | $15.7M | +37% |
| Operating cash flow | $23.3M | −$47.1M | $70.4M | — |
| Free cash flow (OCF − capex) | $19.1M | −$47.1M | $66.1M | — |
| Capital expenditures | $4.3M | $0 | $4.3M | — |
Questions
How much did Madrigal Pharmaceuticals's revenue grow year over year in Q2 2026?
Madrigal Pharmaceuticals's revenue rose $151M (+71%) from $213M in Q2 2025 to $364M in Q2 2026.